盐酸度洛西汀(Duloxetine Hydrochloride) - 药物靶点：NET x SERT_在研适应症：骨关节炎，腰痛，糖尿病周围神经病变_专利_临床

概要

基本信息

简介CYMBALTA®（盐酸度洛西汀）是口服药物，属于选择性5-羟色胺和去甲肾上腺素再摄取抑制剂（SNRI）类。它由礼来公司于2004年首次获得美国批准使用。CYMBALTA®适用于重度抑郁症、成人和7岁及以上的小儿的广泛性焦虑障碍、成人糖尿病周围神经病性疼痛、成人和13岁及以上的小儿纤维肌痛、成人慢性肌肉骨骼疼痛的治疗。其化学名称为(+)-(S)-N-甲基-γ-(1-萘氧基)-2-噻吩丙胺盐酸盐，分子式为C18H19NOS•HCl，分子量为333.88。它通过抑制5-羟色胺和去甲肾上腺素的再摄取发挥作用。

药物类型

小分子化药

别名

(3S)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propan-1-amine、(S)-duloxetine、Ariclaim

+ [16]

靶点

NET x SERT

作用机制

NET抑制剂(去甲肾上腺素转运蛋白抑制剂)、SERT抑制剂(5-羟色胺转运体抑制剂)

治疗领域

免疫系统疾病神经系统疾病内分泌与代谢疾病+ [3]

在研适应症

骨关节炎腰痛糖尿病周围神经病变+ [10]

非在研适应症

创伤性脑损伤慢性骨关节炎慢性疼痛+ [9]

原研机构

Eli Lilly & Co.

在研机构

Sun Pharmaceutical Industries Ltd.

Zentiva ksEli Lilly Nederland BV

+ [3]

非在研机构

Boehringer Ingelheim International GmbH

Boehringer Ingelheim GmbH

Esteve Pharmaceuticals S.A.

+ [2]

最高研发阶段批准上市

首次获批日期

美国 (2004-08-03),

重度抑郁症

最高研发阶段(中国)批准上市

特殊审评优先审评 (中国)

登录后查看时间轴

结构/序列

分子式C18H20ClNOS

InChIKeyBFFSMCNJSOPUAY-LMOVPXPDSA-N

CAS号136434-34-9

关联

555

项与盐酸度洛西汀相关的临床试验

NCT06614322

/ Not yet recruiting临床2期IIT

Sensory Phenotyping to Enhance Neuropathic Pain Drug Development (SPENDD): a Randomized, Double-blinded Cross-over Clinical Trial Aimed At Investigating Whether Bedside Quantitative Sensory Testing Can Predict Response to Analgesics.

The goal of this clinical trial is to determine whether quantitative sensory testing (QST) can be used to classify participants into pain sub-groups and predict who will respond best to certain pain treatments in participants with painful peripheral neuropathy.
The analgesic effect is evaluated by measuring pain intensity and Patient Global Impression of Change (PGIC).
This study is a 3-period cross-over trial. This means researchers will compare 3 different drugs (pregabalin, duloxetine, and placebo) over a period of 19 weeks.
Participants will:
* Undergo a quantitative sensory testing (QST) exam.
* Provide a blood sample.
* Complete questionnaires on the computer.
* Take the study drug as instructed.

开始日期2025-09-01

申办/合作机构

University of Rochester

[+1]

NCT06807866

/ Not yet recruiting临床4期IIT

Use of Duloxetine for Perioperative Pain Control After Total Hip Arthroplasty: Randomized Controlled Clinical Trial (RCT)

The primary objective of this study is to compare total narcotic intake standardized via milligram morphine equivalents between duloxetine and placebo cohorts after a total hip arthroplasty.

开始日期2025-04-01

申办/合作机构

University of Miami

NCT05976347

/ Not yet recruiting临床4期IIT

Identifying and Treating Depression in the Orthopaedic Trauma Population

The goal of this trial is to pilot a way for orthopaedic surgeons to safely screen for depression and provide treatment for depression with medication. The main questions it aims to answer are:
1. What are the outcomes of patients who screen positive for depressive symptoms and are prescribed either an Selective serotonin reuptake inhibitors (SSRI) or serotonin and norepinephrine reuptake inhibitors (SNRI).
2. What are the outcomes of patients who screen positive for depressive symptoms and choose not to pursue treatment with medication?

开始日期2025-04-01

申办/合作机构

Wake Forest School of Medicine

100 项与盐酸度洛西汀相关的临床结果

登录后查看更多信息

100 项与盐酸度洛西汀相关的转化医学

登录后查看更多信息

100 项与盐酸度洛西汀相关的专利（医药）

登录后查看更多信息

4,791

项与盐酸度洛西汀相关的文献（医药）

2025-04-01·JOURNAL OF CLINICAL EPIDEMIOLOGY

Incomplete reporting of adverse events in duloxetine trials: a meta-research survey of randomized controlled trials vs placebo

Article

作者: Jutel, A ; Rolland, P ; Douget, K ; Naudet, F ; Roy, J-C

OBJECTIVE:

Relying on published data alone might be insufficient for meta-analyses to be reliable and trustworthy since selective outcome reporting is common, especially for adverse events. We investigated the existence of selective reporting and its potential for bias in a case study exploring adverse events of duloxetine in adults.

STUDY DESIGN AND SETTING:

We systematically searched all previous meta-analyses/pooled analyses on duloxetine published on PubMed for 7 indications approved by the American and European health authorities. We included all randomized controlled trials (RCT) versus placebo. For each RCT, we extracted the number of serious adverse events (SAE), adverse events (AE), drop-outs (DO) and drop-outs for safety reasons (DOSR) using 4 information sources: published articles, clinical study registries, clinical study reports and data available in meta-analyses/pooled analyses. To assess the range of differences resulting from these 4 extraction strategies, we performed 4 meta-analyses using random effect models as well as a complete meta-analysis combining all sources.

RESULTS:

70 RCTs (including 24,330 patients) were included. Of those, SAEs were identified for 42 studies (61%) in published articles, 58 (84%) in study reports (8 study reports were not retrieved), 24 (34.7%) in registries, and 21 (30.4%) in meta-analyses/pooled analyses.For 2 (2.9%), 2 (2.9%), 2 (2.9%) and 1 (1.4%) studies, we found respectively no data on SAEs, AEs, DOs and DOSRs in any sources. Discrepant results across sources were found in 24 (34.5%), 20 (28.5%), 13 (18.6%) and 9 (12.8%) studies, respectively for SAEs, AEs, DOs and DOSRs. Despite variations in point estimates and their 95% confidence intervals, we did not find different results in the conclusions of meta-analyses depending on the different information sources used, except for DOs, for which no effect was found using results published in registries, in contrast to other information sources.

CONCLUSION:

None of the four information sources provided complete retrieval of safety results for duloxetine in adults across various indications. However, we did not find strong evidence that this under-reporting leads to different conclusions in meta-analyses. Nonetheless, this finding remains uncertain, as we were unable to obtain complete information for all studies despite extensive searches.

2025-04-01·JOURNAL OF AFFECTIVE DISORDERS

Metabolomics signatures of serotonin reuptake inhibitor (escitalopram), serotonin norepinephrine reuptake inhibitor (duloxetine) and cognitive-behavioral therapy on key neurotransmitter pathways in major depressive disorder

Article

作者: Mayberg, Helen S ; Marur, Vasant R ; Bhattacharyya, Sudeepa ; Craighead, W Edward ; Belenky, Marina ; Kaddurah-Daouk, Rima ; Sniatynski, Matthew J ; Dunlop, Boadie W ; Rush, A John ; Kristal, Bruce S ; MahmoudianDehkordi, Siamak

Metabolomics provides powerful tools that can inform about heterogeneity in disease and response to treatments. In this exploratory study, we employed an electrochemistry-based targeted metabolomics platform to assess the metabolic effects of three randomly-assigned treatments: escitalopram, duloxetine, and Cognitive-Behavioral Therapy (CBT) in 163 treatment-naïve outpatients with major depressive disorder. Serum samples from baseline and 12 weeks post-treatment were analyzed using targeted liquid chromatography-electrochemistry for metabolites related to tryptophan, tyrosine metabolism and related pathways. Changes in metabolite concentrations related to each treatment arm were identified and compared to define metabolic signatures of exposure. In addition, association between metabolites and depressive symptom severity (assessed with the 17-item Hamilton Rating Scale for Depression [HRSD₁₇]) and anxiety symptom severity (assessed with the 14-item Hamilton Rating Scale for Anxiety [HRSA₁₄]) were evaluated, both at baseline and after 12 weeks of treatment. Significant reductions in serum serotonin level and increases in tryptophan-derived indoles that are gut bacterially derived were observed with escitalopram and duloxetine arms but not in CBT arm. These include indole-3-propionic acid (I3PA), indole-3-lactic acid (I3LA) and Indoxyl sulfate (IS), a uremic toxin. Purine-related metabolites were decreased across all arms. Different metabolites correlated with improved symptoms in the different treatment arms revealing potentially different mechanisms between response to antidepressant medications and to CBT.

2025-03-01·AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

A Systematic Review of Antidepressants and Psychotherapy Commonly Used in the Treatment of Late Life Depression for Their Effects on Cognition

Article

作者: Gandelman, Jason A ; Gandelman, Jason A. ; Gandelman, Jason ; Nelson, J Craig ; Mackin, R Scott ; Nelson, J. Craig ; Mackin, R. Scott

Cognitive dysfunction is common in late life depression (LLD) and is a major risk factor for dementia. Recent studies show limited improvement in cognition with commonly employed treatments for LLD, contradicting the notion that cognition "returns to normal" with treatment. However, findings differ with the treatments used. The aim of this study is to perform a systematic review of studies of antidepressants and psychotherapies commonly employed in LLD to determine their effects on cognition, particularly processing speed, memory, and executive function. We searched for trials of acute phase treatment, in nondemented individuals 60 years and older with unipolar nonpsychotic Major Depressive Disorder, that assessed cognitive performance with neuropsychological tests before and after treatment. We compared the magnitude of change in cognition by examining within group effect sizes. Six antidepressant trials and two psychotherapy trials (both using Problem Solving Therapy)(PST) provided relatively comparable data that allowed for quantitative comparison. Nine other antidepressant trials provided descriptive findings. Sertraline and vortioxetine had significant positive effects on processing speed and memory. Duloxetine had significant effects on memory. The most selective SRIs-citalopram and escitalopram-had minimal effects on cognition and citalopram had adverse effects in depression nonresponders. PST had modest effects on processing speed and no effect on memory. Effects of practice and improvement in depression on cognition are examined. In all but one study, cognition was a secondary outcome and various quality indicators (e.g. blinding cognitive assessment to treatment) were often not reported. As a consequence, these findings must be considered preliminary.

162

项与盐酸度洛西汀相关的新闻（医药）

2025-01-11

·药闻康策

二甲双胍不到3分钱！广东联盟药品集采拟中选结果出炉

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策广东国采接续联盟参与的省份：安徽、福建、江西、湖北、湖南、广东、重庆、四川、云南、西藏、陕西、甘肃、新疆。各有关企业：根据《广东联盟阿哌沙班片等药品集中带量采购文件（GDYPLM202401）》有关要求和工作安排，现公示广东联盟阿哌沙班片等药品集中带量采购项目申报品规的拟中选/拟中选限量结果（详见附件），公示时间为2025年1月10日至2025年1月21日17:00。本次集采项目，拟中选/拟中选限量企业“供应清单”的中选结果与价格将在后续另行公布。如对公示内容有异议，请企业在公示期内登录广州药品集团采购平台，通过救济渠道-申投诉管理模块提交申诉，并依法依规提供合法有效的证明材料（申请材料应逐页加盖企业公章）；逾期提交的、未提供相应证明材料的或未按照规定途径提交的复核申请，广州药品集团采购平台将不予受理。艾司奥美拉唑镁肠溶胶囊，艾司奥美拉唑镁肠溶片，吡嗪酰胺片，布洛芬片，盐酸度洛西汀肠溶胶囊，恩格列净片，盐酸普拉克索缓释片，普瑞巴林胶囊，羟苯磺酸钙片，羟苯磺酸钙胶囊，羟苯磺酸钙分散片，替格瑞洛片，替米沙坦片，吸入用硫酸沙丁胺醇溶液，左氧氟沙星片，共记15个产品和12月份的江苏联盟重合。广东联盟阿哌沙班片等药品集中带量采购拟中选结果 4分钱以下的产品也是有一些的: (来源：风云药谈) (来源:要酷科技）有需要《广东联盟阿哌沙班片等药品集中带量采购拟中选结果》完整Excel表格，请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

带量采购

2025-01-09

·drugs

Gabapentin Doesn't Increase Fall Risk, Study Suggests

THURSDAY, Jan. 9, 2025 -- A pain-relieving medication might be safer for seniors than first thought. A new study published Jan. 7 in the Annals of Internal Medicine says Gabapentin is widely used to help treat chronic pain and nerve pain, particularly as an alternative to opioid painkillers. However, some have argued that gabapentin shouldn’t be prescribed to seniors, as it might increase their risk of damaging falls . Those concerns are baseless, according to the study. The study’s results show that gabapentin “was associated with fewer fall-related health care visits and … was not associated with an increase in more severe fall-related events,” concluded a research team led by Dr. Alexander Chaitoff , an assistant professor of internal medicine with the University of Michigan. “These considerations should be incorporated into conversations with patients who are considering starting gabapentin treatment,” the team added. Nearly 50 million prescriptions for gabapentin were written in 2020, but by 2022 those scripts had fallen by 20% after several studies found that the drug might increase fall risk for seniors. Chaitoff and his colleagues suspected that this risk might be overblown, given that the painful conditions for which gabapentin is prescribed also increases risk of falls. “Neuropathy, the most common indication for which gabapentin is prescribed, is also a known contributor to adverse health events, especially falls,” the researchers noted. The researchers decided to compare the safety of gabapentin against that of duloxetine , another drug prescribed for nerve pain that doesn’t have the same reputation for increasing fall risk. The team gathered data for more than 57,000 seniors 65 or older prescribed either gabapentin or duloxetine between Jan. 2014 and Dec. 2021 for nerve pain related to diabetes , shingles or fibromyalgia. The results showed that gabapentin users actually had a 48% lower overall risk of any falls, compared to those taking duloxetine. However, there was no difference between the two drugs when it came to the risk of experiencing a severe fall. “Although we cannot claim that gabapentin does not lead to higher risk for falls at any time, our study does suggest that the risks of gabapentin as they relate to fall risk in the first 6 months of initiation are not greater, or potentially favorable, versus an alternative medication that might be prescribed instead,” the research team concluded. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果上市批准

2025-01-07

·医学新视点

骨关节炎该怎么治？多篇指南送你答案

骨关节炎（OA）发病率高、发病部位多并且无特效治疗，临床实践中往往从包括药物、手术、非药物以及生活方式干预等丰富多样的措施对OA进行管理。由于OA发病愈加普遍，不同学术组织推出的实践指南让人眼花缭乱。不用着急，看这一篇OA最佳证据总结就够啦！国际指南中的OA共识墨尔本大学的研究团队在对20份高标准的临床实践指南（CPG）分析后，纳入11部关于髋/膝/手/盂肱以及多关节OA的高质量CPG归为高质量指南。结合最佳证据总结的方法学，11部高质量CPG从药物、理疗以及生活方式干预等具体管理措施的角度，列出了4个等级的建议：应该做 OA的管理应以患者为中心，并包括锻炼、患者教育和适当情况下减肥管理措施。对于非手术疗效不佳的致残性OA，建议使用非甾体类抗炎药和手术治疗。手OA患者应使用矫形器。可以做平衡练习、瑜伽、辅助器材、体重管理和锻炼、认知行为疗法、封闭治疗（膝/手关节OA激素注射）、超声引导下注射、抗抑郁药（度洛西汀）、术前理疗、氨甲环酸、神经麻醉以及手术前后理疗。不要做超声治疗、双膦酸盐、秋水仙碱、甲氨蝶呤、双醋瑞因、葡萄糖氨和软骨素（髋/多关节OA）以及术后持续被动运动和冷冻治疗。无共识水/浴、冷热疗、电疗、绷带及支具、矫形鞋、局部外用辣椒素、封闭治疗（髋/多关节OA激素注射）、关节内注射透明质酸、富血小板注射、干细胞疗法、对乙酰氨基酚、口服阿片类药物、葡萄糖氨和软骨素（盂肱关节OA）以及保健品。求同存异的OA管理结合中国的临床实际，优化OA的非药物及非手术管理更具意义，中国目前的OA指南又如何推荐呢？以中华医学会《中国骨关节炎诊疗指南（2021年版）》为例。 ▲中华医学会2021版OA诊疗指南的指导原则在诊疗理念和实践细则上，该指南博采众长并结合中国实际，共列出了30条推荐意见，对OA的高危人群特征、OA特征、OA诊疗选项、疼痛管理以及手术时机等关键问题进行了推荐。 ▲骨关节炎诊疗指南（2021年版）推荐意见汇总表相关阅读膝盖痛？JAMA综述：膝骨关节炎、半月板撕裂……3大常见病因及治疗，一文详解中国患者超千万！《自然》子刊：治疗类风湿关节炎，如何才算“达标”？ 1次注射，3个多月持续缓解关节疼痛、僵硬！《柳叶刀》子刊：膝关节炎长效疗法打破现有治疗局限缓解关节疼痛，改善功能！NEJM：锻炼好？还是手术更有效？既能减肥，又可改善关节炎！NEJM重磅：司美格鲁肽再添新证欢迎投稿：学术成果、前沿进展、临床干货等主题均可，点此了解投稿详情。参考资料（可上下滑动查看） [1]Conley B, Bunzli S, Bullen J, et al. Core recommendations for osteoarthritis care: a systematic review of clinical practice guidelines[J]. Arthritis care & research, 2023. [2]Hagen K B, Smedslund G, Østerås N, et al. Quality of community‐based osteoarthritis care: a systematic review and meta‐analysis[J]. Arthritis care & research, 2016, 68(10): 1443-1452. [3]Brand C A, Harrison C, Tropea J, et al. Management of osteoarthritis in general practice in Australia[J]. Arthritis care & research, 2014, 66(4): 551-558. [4]中华医学会骨科学分会关节外科学组,中国医师协会骨科医师分会骨关节炎学组,国家老年疾病临床医学研究中心（湘雅医院）,中华骨科杂志编辑部.中国骨关节炎诊疗指南（2021年版）[J].中华骨科杂志,2021,41(18):1291-1314.DOI:10.3760/cma.j.cn121113-20210624-00424. [5]Hinman R S, McCrory P, Pirotta M, et al. Acupuncture for chronic knee pain: a randomized clinical trial[J]. Jama, 2014, 312(13): 1313-1322. [6]Lao L, Yeung W F., G. David Baxter, et al. Treating chronic knee pain with acupuncture[J]. JAMA, 2015, 313(6): 627-628. [7]Kolasinski S L, Neogi T, Hochberg M C, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the management of osteoarthritis of the hand, hip, and knee[J]. Arthritis & rheumatology, 2020, 72(2): 220-233. 免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。分享，点赞，在看，传递医学新知

细胞疗法

100 项与盐酸度洛西汀相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D01179	盐酸度洛西汀	N06AX21	DB00476

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
骨关节炎	日本	Shionogi & Co., Ltd.	2016-12-19
腰痛	日本	Shionogi & Co., Ltd.	2016-03-18
糖尿病周围神经病变	美国	Eli Lilly & Co.	2014-10-16
糖尿病性神经病变	日本	Shionogi & Co., Ltd.	2012-02-22
慢性肌肉骨骼疼痛	美国	Eli Lilly & Co.	2010-11-04
纤维肌痛	美国	Eli Lilly & Co.	2008-06-13
焦虑症	澳大利亚	Eli Lilly & Co.	2007-03-14
神经痛	澳大利亚	Eli Lilly & Co.	2007-03-14
抑郁症	中国	Eli Lilly & Co.	2006-07-28
广泛性焦虑障碍	欧盟	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	欧盟	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	冰岛	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	冰岛	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	列支敦士登	Eli Lilly Nederland BV	2004-12-17
广泛性焦虑障碍	列支敦士登	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	挪威	Esteve Pharmaceuticals S.A.	2004-12-17
广泛性焦虑障碍	挪威	Eli Lilly Nederland BV	2004-12-17
糖尿病周围神经性疼痛	欧盟	Eli Lilly Nederland BV	2004-08-11
糖尿病周围神经性疼痛	冰岛	Eli Lilly Nederland BV	2004-08-11
糖尿病周围神经性疼痛	列支敦士登	Eli Lilly Nederland BV	2004-08-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
慢性骨关节炎	临床3期	日本	Eli Lilly & Co.	2014-10-01
慢性骨关节炎	临床3期	日本	Shionogi, Inc.	2014-10-01
慢性疼痛	临床3期	中国	Eli Lilly & Co.	2013-09-01
髌骨股骨疼痛综合征	临床3期	美国	Eli Lilly & Co.	2009-11-01
髌骨股骨疼痛综合征	临床3期	波多黎各	Eli Lilly & Co.	2009-11-01
肥胖	临床3期	美国	Eli Lilly & Co.	2009-09-01
多发性硬化症	临床3期	美国	Eli Lilly & Co.	2008-10-01
多发性硬化症	临床3期	比利时	Eli Lilly & Co.	2008-10-01
多发性硬化症	临床3期	加拿大	Eli Lilly & Co.	2008-10-01
多发性硬化症	临床3期	波兰	Eli Lilly & Co.	2008-10-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03249558 (Duloxetine, CTgov)	临床4期	腰痛 \| 慢性疼痛 \| 颈部疼痛	81	Duloxetine+Morphine (Morphine, Duloxetine)	淵願顧鬱衊夢觸積觸獵(鏇網遞鹽襯齋製積夢夢) = 網願築顧觸衊鹽衊餘鏇襯鑰廠窪憲鏇簾觸鏇遞 (艱艱網夢製鹹艱網繭範, 糧齋鹽鏇壓衊鑰壓範顧 ~ 鏇觸襯鬱繭網構鹽築選) 更多	-	2024-11-14
				Placebo+Morphine (Morphine, Placebo Duloxetine)	淵願顧鬱衊夢觸積觸獵(鏇網遞鹽襯齋製積夢夢) = 製夢製齋簾製積簾淵選襯鑰廠窪憲鏇簾觸鏇遞 (艱艱網夢製鹹艱網繭範, 鏇獵夢築衊積網糧鬱窪 ~ 醖鏇鏇範醖齋網糧構網) 更多
NCT04313335 (PROCESS Trial, Pubmed \| Clin Infect Dis)	N/A	疱疹后神经痛 \| 带状疱疹	-	Duloxetine	製廠夢鹹餘遞壓積餘憲(遞鹹膚獵顧鹹廠憲鹹齋) = 構夢選顧獵憲鏇衊鹽鑰衊齋獵鑰顧齋廠齋廠廠 (窪艱鏇齋簾艱鬱衊齋衊 )	-	2024-04-10
				Duloxetine (Control)	製廠夢鹹餘遞壓積餘憲(遞鹹膚獵顧鹹廠憲鹹齋) = 醖築築築顧鏇繭壓鏇齋衊齋獵鑰顧齋廠齋廠廠 (窪艱鏇齋簾艱鬱衊齋衊 )
NCT02229825 (CTgov)	临床4期	重度抑郁症	339	Duloxetine (60 mg Duloxetine)	襯糧艱鹹製構築願範選(壓獵衊衊築夢鏇淵簾醖) = 鏇蓋淵遞窪積網壓艱壓範簾醖獵蓋襯願衊蓋繭 (鹹餘願衊繭憲顧簾鏇觸, 觸願夢鏇遞憲廠築襯範 ~ 鏇顧膚築衊淵壓範襯膚) 更多	-	2023-10-23
				Duloxetine (120 mg Duloxetine)	襯糧艱鹹製構築願範選(壓獵衊衊築夢鏇淵簾醖) = 築夢窪醖鹹糧鬱廠願鬱範簾醖獵蓋襯願衊蓋繭 (鹹餘願衊繭憲顧簾鏇觸, 製鬱網淵衊壓觸窪壓鏇 ~ 簾醖簾網餘餘鹹膚齋壓) 更多
NCT03395353 (Pubmed \| Drug Metab Pharmacokinet)	临床3期	重度抑郁症	151	duloxetine (Japanese pediatric patients with major depressive disorder)	觸網網淵繭獵醖範糧鏇(衊鬱淵鹹鏇網醖淵壓壓) = 積壓鬱憲鑰蓋鏇鏇繭壓網鬱蓋鹽構積範鏇糧簾 (鬱築衊醖繭遞選鏇繭築 ) 更多	-	2023-02-15
NCT04178993 (CTgov)	临床1期	甲基苯丙胺依赖	8	Placebo oral capsule+Methylphenidate+Methamphetamine (Placebo Comparator: Placebo)	鑰選窪選鹹鹽獵簾廠夢(衊製鬱獵選糧遞網艱衊) = 窪繭築鬱選醖網艱艱淵選壓衊憲糧憲壓鹽襯構 (鹽選鹽鹽製蓋淵繭選顧, 選壓願鏇鏇鹽選窪艱齋 ~ 糧築積襯觸窪網壓製築) 更多	-	2023-01-09
				Placebo oral capsule+Methylphenidate+Duloxetine+Methamphetamine (Active Comparator: Duloxetine)	壓鬱憲衊餘憲憲網鹽齋(糧顧鹹選餘醖簾餘繭餘) = 製淵網製糧鏇鹹構衊衊遞衊齋積壓簾憲構願鹹 (廠選構鹽積壓鹹糧鑰窪, 餘鏇餘襯築夢鏇鑰糧構 ~ 選餘鏇膚衊顧範衊願鑰) 更多
CTRI/2021/03/031875 (Pubmed \| Pain Med)	N/A	疼痛	82	Duloxetine	繭廠築鑰壓蓋選憲簾糧(製膚製築廠蓋繭積鏇夢) = 簾範鹹廠廠窪餘憲醖壓廠衊築獵齋夢築襯鹽鏇 (積蓋範網壓襯蓋鹹蓋願 )	积极	2022-11-21
				Placebo	繭廠築鑰壓蓋選憲簾糧(製膚製築廠蓋繭積鏇夢) = 糧簾構艱簾憲餘憲簾鏇廠衊築獵齋夢築襯鹽鏇 (積蓋範網壓襯蓋鹹蓋願 )
NCT03271151 (CTgov)	临床4期	关节疾病 \| 急性疼痛 \| 慢性疼痛	160	Cymbalta (Duloxetine ("Cymbalta"))	襯構鹹淵鏇鹽憲選艱糧(淵齋願壓窪簾醖鏇壓淵) = 構衊簾廠網壓膚觸蓋鏇鹹鑰製繭鬱鬱築顧蓋積 (醖獵範製鏇齋衊艱鹽憲, 憲願範構選選壓顧憲蓋 ~ 網鏇夢糧憲顧觸選艱膚) 更多	-	2022-04-26
				Placebo (Placebo)	襯構鹹淵鏇鹽憲選艱糧(淵齋願壓窪簾醖鏇壓淵) = 網憲獵繭鏇選鏇糧鹽築鹹鑰製繭鬱鬱築顧蓋積 (醖獵範製鏇齋衊艱鹽憲, 繭鏇窪憲鏇築構觸廠願 ~ 鏇範繭選齋積衊遞選遞) 更多
NCT04697693 (CTgov)	临床4期	重度抑郁症 \| 创伤后应激障碍	1	Escitalopram+Duloxetine	衊網鹹製選製顧蓋窪鏇(簾夢窪蓋壓鏇醖鏇糧製) = 糧簾醖餘觸糧夢鏇廠築鏇積淵淵鑰範鹽獵觸壓 (齋壓齋膚淵齋鬱膚獵遞, 構鹽淵築築鏇窪鹹憲鹽 ~ 壓糧繭鏇顧齋餘淵遞鏇) 更多	-	2022-03-28
NCT03321006 (CTgov)	临床4期	认知功能障碍 \| 抑郁症 \| 老年性耳聋	25	escitalopram+Audeo B-R 90 hearing aid device (Sham)+Duloxetine (Antidepressant (AD) + Low Amplification (Sham) Hearing Aids)	齋壓網糧鹽憲淵壓築襯(範齋築醖網壓窪廠鏇窪) = 齋鹽鏇餘夢憲鏇襯獵衊獵憲衊獵夢觸襯願範膚 (窪簾鬱膚構膚構鑰夢鹹, 夢選夢淵鹹憲餘膚齋襯 ~ 簾鑰窪窪觸繭構遞廠積) 更多	-	2021-08-19
				escitalopram+Phonak Audeo B-R 90 hearing aid device (Active)+Duloxetine (Antidepressant (AD) + Full Amplification Hearing Aids)	齋壓網糧鹽憲淵壓築襯(範齋築醖網壓窪廠鏇窪) = 糧觸壓鏇顧夢願構醖壓獵憲衊獵夢觸襯願範膚 (窪簾鬱膚構膚構鑰夢鹹, 構夢艱範襯醖鬱襯齋積 ~ 蓋顧鏇繭築選鑰膚蓋鏇) 更多
NCT03395353 (CTgov)	临床3期	抑郁症	151	Duloxetine (Duloxetine)	選鑰簾鹹襯醖範鏇簾願(艱選鹹夢蓋顧餘獵夢鹽) = 鹹膚淵積顧齋鬱壓願簾積範獵簾願艱衊願鹽顧 (醖糧範膚觸廠鹽夢積窪, 製獵構窪積鏇築選壓衊 ~ 顧餘廠餘構鹽願鏇襯壓) 更多	-	2021-06-18
				Duloxetine (Duloxetine 40 mg (9 to 11 Years Old))	襯壓膚鹽鏇壓餘壓簾鬱(齋積簾窪繭壓繭艱遞選) = 艱衊願餘鹹廠餘獵艱蓋壓醖範鹽憲鏇醖製淵鏇 (夢構艱襯鬱繭鑰願憲夢, 鹹築憲構遞獵選遞鏇廠 ~ 衊築鑰鏇繭淵繭鏇餘醖)